Search

Your search keyword '"Birrer, Michael"' showing total 1,893 results

Search Constraints

Start Over You searched for: Author "Birrer, Michael" Remove constraint Author: "Birrer, Michael"
1,893 results on '"Birrer, Michael"'

Search Results

53. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

57. Molecular, Metabolic, and Subcellular Mapping of the Tumor Immune Microenvironment via 3D Targeted and Non-Targeted Multiplex Multi-Omics Analyses

58. Pan-cancer proteogenomics characterization of tumor immunity

59. Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer

60. Common variants at 19p13 are associated with susceptibility to ovarian cancer (vol 42, pg 880, 2010)

61. Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer.

63. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study

64. Impact of Homologous Recombination Status and Responses With Veliparib Combined With First-Line Chemotherapy in Ovarian Cancer in the Phase 3 VELIA/GOG-3005 Study

65. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

66. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

68. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

70. Deep learning integrates histopathology and proteogenomics at a pan-cancer level

71. Proteogenomic insights suggest druggable pathways in endometrial carcinoma

73. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

74. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

75. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

76. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

77. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

78. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

79. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

80. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

81. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

82. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

83. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

84. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.

85. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.

86. Inherited variants in regulatory T cell genes and outcome of ovarian cancer.

87. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31

89. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.

90. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study

91. Common variants at 19p13 are associated with susceptibility to ovarian cancer.

92. Pan-cancer proteogenomics connects oncogenic drivers to functional states

93. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin

94. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation

95. Proteogenomic data and resources for pan-cancer analysis

99. Egr1 regulates the coordinated expression of numerous EGF receptor target genes as identified by ChIP-on-chip

Catalog

Books, media, physical & digital resources